Revvity Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.6%projected annual EPS growth
Analyst Coverage
15analysts covering
FY EPS (est.)
$5.35next fiscal year
Monitoring Framework
Key Performance Indicators
Pro Forma Organic Revenue Growth Quarterly600.0%Target: 3% to 4% for FY2026
Pro Forma Adjusted Operating Margin Quarterly2,400.0%
SaaS Annual Recurring Revenue (ARR) Growth QuarterlyTarget: Strong double-digit growth
Watch Items
- China Immunodiagnostics Divestiture ProgressTrigger: Definitive agreement expected to be signed in Q2 2026 and divestiture completed in 2027Action: Monitor regulatory approvals, transaction terms, and the finalization of the minority interest retention.
- Life Sciences Segment RecoveryAction: Assess academic and biotech funding environments, instrument replacement cycles, and R&D spending levels.
Research as of 2 Sep 2026